Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sevoflurane
Drug ID BADD_D02015
Description Sevoflurane, also called fluoromethyl, is an ether inhalation anaesthetic agent used for the induction and maintenance of general anesthesia. It is a volatile, non-flammable, non-irritant, and easy-to-administer compound with a low solubility profile and blood-to-gas partition coefficient.
Indications and Usage Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
Marketing Status approved; vet_approved
ATC Code N01AB08
DrugBank ID DB01236
KEGG ID D00547
MeSH ID D000077149
PubChem ID 5206
TTD Drug ID D0W6ZF
NDC Product Code 12164-009; 10019-653; 0074-4456; 0781-6160; 66794-012; 54122-4486; 66794-015; 66794-022; 10019-651; 12164-005; 42677-110; 57884-0036; 10019-655; 10019-657
UNII 38LVP0K73A
Synonyms Sevoflurane | Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl Ether | Fluoromethyl Hexafluoroisopropyl Ether | Sevorane | Ultane | BAX 3084
Chemical Information
Molecular Formula C4H3F7O
CAS Registry Number 28523-86-6
SMILES C(OC(C(F)(F)F)C(F)(F)F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Supraventricular extrasystoles02.03.03.011--Not Available
Supraventricular tachycardia02.03.03.0120.000447%
Swelling face10.01.05.018; 08.01.03.100; 23.04.01.018--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.0070.001161%Not Available
Tachypnoea22.02.01.0140.000179%Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.0020.000447%Not Available
Torsade de pointes02.03.04.0050.000179%Not Available
Trismus17.01.03.004; 15.05.04.0040.000179%
Urethral disorder20.07.01.002--Not Available
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001--Not Available
Urine abnormality20.02.01.013--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular fibrillation02.03.04.0080.000357%
Ventricular tachycardia02.03.04.010--
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Tubulointerstitial nephritis20.05.02.002--Not Available
Electrocardiogram ST-T segment depression13.14.05.038--Not Available
Neonatal hypoxia18.04.15.002; 22.11.02.0020.000268%Not Available
Tonic clonic movements17.12.03.006--Not Available
Haemodynamic instability24.03.02.0060.000179%Not Available
Musculoskeletal stiffness15.03.05.0270.000179%Not Available
Haemorrhage24.07.01.0020.000268%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000179%Not Available
Angiopathy24.03.02.007--Not Available
Cardiac disorder02.11.01.003--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene